Total
0
Shares
Mesoblast (ASX:MSB) - Managing Director & CEO, Silviu Itescu - The Market Herald
Managing Director & CEO, Silviu Itescu
Source: Mesoblast
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Mesoblast (MSB) shares have lost more than a third of their value after the U.S. Food and Drug Administration recommended the company's Remestemcel-L treatment should undergo another trial
  • Remestemcel-L aims to treat pediatric steroid-refractory acute graft versus host disease (SR-aGVHD)
  • As there is no known cure for this life-threatening illness in kids, Mesoblast will request a meeting with the FDA to discuss a potential accelerated approval
  • The company expects the meeting to be held within the next month and said any approval depended on a post-approval study
  • Today's pre-market-open announcement comes after the company entered a trading halt ahead of the news yesterday
  • Now that shares have resumed trading, MSB shares have dropped a staggering 38.4 per cent to trade for $3.13 each

Mesoblast (MSB) shares have lost more than a third of their value after the U.S. Food and Drug Administration recommended the company's Remestemcel-L treatment should undergo another trial.

Remestemcel-L aims to treat pediatric steroid-refractory acute graft versus host disease (SR-aGVHD), a life-threatening illness in children under 12. The company is also testing the treatment on severe acute respiratory distress syndrome (ARDS), brought on by COVID-19.

However, while the Oncologic Drugs Advisory Committee (ODAC)1 of the FDA voted nine-to-one that Remestemcel-L was effective in treating SR-aGVHD, the drug administrator still recommended Mesoblast conduct at least one additional randomized, controlled study in patients to provide further evidence of its effectiveness.

In response to the FDA's request for additional testing to be carried out, Mesoblast has announced it will seek an urgent meeting with the agency to request a potential accelerated approval, with any approval dependent on a post-approval study being conducted.

The ASX-200 listed company advised shareholders it expects this next meeting with the FDA to happen within 30 days of the request being sent. It also expects an update on its phase-three trial of Remestemcel-L on the COVID-19 related ARDS in November this year.

“We are working tirelessly to bring remestemcel-L to patients with life threatening inflammatory conditions, including SR-aGVHD and COVID-19 ARDS,”Mesoblast Chief Executive Dr Silviu Itescu stated.

Today's announcement comes after the company entered a trading halt yesterday as it geared up to release the important update to the market.

Now that shares have resumed trading, MSB shares have dropped a staggering 38.4 per cent to trade for $3.13 each at 10:40 am AEST.

MSB by the numbers
More From The Market Herald
Creso Pharma (ASX:CPH) - Creso Pharma - The Market Herald

" Creso Pharma (ASX:CPH) launches ecommerce channels, enters Polish markets

Creso Pharma (CPH) has launched new e-commerce channels and expanded into Poland with a maiden purchase order secured.
Commonwealth Bank (ASX:CBA) - CEO, Matt Comyn - The Market Herald

" Commonwealth Bank (ASX:CBA) faces 30 criminal charges for insurance sales

The investments watchdog has brought 30 criminal charges against Commonwealth Bank (CBA) for its promotion and sale of insurance between 2011 and 2015....
CIMIC Group (ASX:CIM) - Executive Chairman & CEO, Juan Santamaria - The Market Herald

" CIMIC’s (ASX:CIM) CPB Contractors wins Western Sydney Airport bid

CIMIC (CIM) Group company CPB Contractors, with its joint venture partner Acciona, has been chosen to deliver Western Sydney International Airport airside civil
Emyria (ASX:EMD) contracts consultant for psychedelics and MDMA research

" Emyria (ASX:EMD) contracts consultant for psychedelics and MDMA research

Emyria (EMD) has appointed a consultant to support its psychedelic-assisted therapy programs.